{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:05:00Z","timestamp":1789502700363,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Currently, there is a lack of an effective strategy for the prevention of peritoneal metastasis (PM) from locally advanced gastric cancer (AGC). This randomized-controlled study aimed to evaluate the outcome of D2 radical resection with hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally AGC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All enrolled patients were randomly assigned to receive HIPEC plus systemic chemotherapy (HIPEC group) or systemic chemotherapy alone (non-HIPEC group) after radical gastrectomy. HIPEC was performed intraperitoneally with cisplatin (40\u00a0mg\/m<jats:sup>2<\/jats:sup>) within 72\u00a0h after surgery, while systemic chemotherapy based on the SOX regimen (S-1 combined with oxaliplatin) was administered 4\u20136\u00a0weeks after radical surgery. Patterns of recurrence, adverse events, 3-year disease-free survival (DFS), and overall survival (OS) were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 134 patients were enrolled in the present study. The 3-year DFS rate was 73.8% in the HIPEC group, which was significantly higher than that in the non-HIPEC group (61.2%, <jats:italic>P\u2009=\u2009<\/jats:italic>0.031). The 3-year OS rate was 73.9% in the HIPEC group and 77.6% in the non-HIPEC group, with no significant difference (<jats:italic>P\u2009=\u2009<\/jats:italic>0.737). PM was the most common distant metastasis in both groups. The occurrence rate of PM in the HIPEC group was statistically lower than that in the non-HIPEC group (20.9% vs. 40.3%, <jats:italic>P\u2009=\u2009<\/jats:italic>0.015). Grade 3 or 4 adverse events occurred in 19 (14.2%) patients, and there was no significant difference between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Radical surgery followed by HIPEC combined with systemic chemotherapy is a safe and feasible strategy for locally AGC patients and could effectively improve DFS and reduce the occurrence of PM. However, more prospective randomized studies with a large sample size are warranted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was registered with <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.medresman.org.cn\">www.medresman.org.cn<\/jats:ext-link> as ChiCTR2200055966 on 10\/12\/2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05019-z","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:01:47Z","timestamp":1688212907000},"page":"11491-11498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study"],"prefix":"10.1007","volume":"149","clinical-trial-number":[{"clinical-trial-number":"chictr2200055966","registry":"10.18810\/chictr"}],"author":[{"given":"Pengfei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiguo","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengjiao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"5019_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315\u2013321. https:\/\/doi.org\/10.1016\/s0140-6736(11)61873-4","journal-title":"Lancet"},{"key":"5019_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/s12885-019-6125-z","volume":"19","author":"MK Beeharry","year":"2019","unstructured":"Beeharry MK, Zhu ZL, Liu WT et al (2019) Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer 19:932. https:\/\/doi.org\/10.1186\/s12885-019-6125-z","journal-title":"BMC Cancer"},{"key":"5019_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00428-015-1734-7","volume":"466","author":"U Bieri","year":"2015","unstructured":"Bieri U, Moch H, Dehler S, Korol D, Rohrmann S (2015) Changes in autopsy rates among cancer patients and their impact on cancer statistics from a public health point of view: a longitudinal study from 1980 to 2010 with data from Cancer Registry Zurich. Virch Arch 466:637\u2013643. https:\/\/doi.org\/10.1007\/s00428-015-1734-7","journal-title":"Virch Arch"},{"key":"5019_CR4","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/jco.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V et al (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37:2028\u20132040. https:\/\/doi.org\/10.1200\/jco.18.01688","journal-title":"J Clin Oncol"},{"key":"5019_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101685","author":"HJF Brenkman","year":"2019","unstructured":"Brenkman HJF, P\u00e4eva M, van Hillegersberg R, Ruurda JP, Haj Mohammad N (2019) Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer-a systematic review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8101685","journal-title":"J Clin Med"},{"key":"5019_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1097\/md.0000000000011949","volume":"97","author":"Z Cai","year":"2018","unstructured":"Cai Z, Cai Z, He T et al (2018) Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer: a systematic review and network meta-analysis protocol. Medicine (baltimore) 97:1949. https:\/\/doi.org\/10.1097\/md.0000000000011949","journal-title":"Medicine (baltimore)"},{"key":"5019_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","volume":"45","author":"W Ceelen","year":"2019","unstructured":"Ceelen W (2019) HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol 45:400\u2013402. https:\/\/doi.org\/10.1016\/j.ejso.2018.10.542","journal-title":"Eur J Surg Oncol"},{"key":"5019_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3748\/wjg.v22.i3.1139","volume":"22","author":"F Coccolini","year":"2016","unstructured":"Coccolini F, Montori G, Ceresoli M et al (2016) Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol 22:1139\u20131159. https:\/\/doi.org\/10.3748\/wjg.v22.i3.1139","journal-title":"World J Gastroenterol"},{"key":"5019_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M et al (2021) Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7:91. https:\/\/doi.org\/10.1038\/s41572-021-00326-6","journal-title":"Nat Rev Dis Primers"},{"key":"5019_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1477-7819-10-195","volume":"10","author":"WL Costa Jr","year":"2012","unstructured":"Costa WL Jr, Coimbra FJ, Ribeiro HS et al (2012) Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol 10:195. https:\/\/doi.org\/10.1186\/1477-7819-10-195","journal-title":"World J Surg Oncol"},{"key":"5019_CR11","unstructured":"CTCAE (2010) Common terminology criteria for adverse events version 4.0 (CTCAE V. 4.0). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"5019_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.soc.2018.02.006","volume":"27","author":"FS Dahdaleh","year":"2018","unstructured":"Dahdaleh FS, Turaga KK (2018) Evolving treatment strategies and outcomes in advanced gastric cancer with peritoneal metastasis. Surg Oncol Clin N Am 27:519\u2013537. https:\/\/doi.org\/10.1016\/j.soc.2018.02.006","journal-title":"Surg Oncol Clin N Am"},{"key":"5019_CR13","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s13304-022-01376-5","volume":"74","author":"H Deng","year":"2022","unstructured":"Deng H, Li B, Qin X (2022) The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with\/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials. Updates Surg 74:1805\u20131816. https:\/\/doi.org\/10.1007\/s13304-022-01376-5","journal-title":"Updates Surg"},{"key":"5019_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio J, Chao J, Melstrom L et al (2017) The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 79:1\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.030","journal-title":"Eur J Cancer"},{"key":"5019_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg"},{"key":"5019_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/jso.25823","volume":"121","author":"TP Diniz","year":"2020","unstructured":"Diniz TP, da Costa WL, de Fonseca Jesus VH et al (2020) Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis. J Surg Oncol 121:823\u2013832. https:\/\/doi.org\/10.1002\/jso.25823","journal-title":"J Surg Oncol"},{"key":"5019_CR17","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1245\/s10434-018-6336-6","volume":"25","author":"RM Dodson","year":"2018","unstructured":"Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA (2018) Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 25:2152\u20132158. https:\/\/doi.org\/10.1245\/s10434-018-6336-6","journal-title":"Ann Surg Oncol"},{"key":"5019_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10120-022-01286-w","volume":"25","author":"H Hasegawa","year":"2022","unstructured":"Hasegawa H, Shitara K, Takiguchi S et al (2022) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer 25:619\u2013628. https:\/\/doi.org\/10.1007\/s10120-022-01286-w","journal-title":"Gastric Cancer"},{"key":"5019_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000012016","volume":"57","author":"K Hirose","year":"1999","unstructured":"Hirose K, Katayama K, Iida A et al (1999) Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology 57:106\u2013114. https:\/\/doi.org\/10.1159\/000012016","journal-title":"Oncology"},{"key":"5019_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"5019_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"JGCA","year":"2017","unstructured":"JGCA (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1\u201319. https:\/\/doi.org\/10.1007\/s10120-016-0622-4","journal-title":"Gastric Cancer"},{"key":"5019_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71:264\u2013279. https:\/\/doi.org\/10.3322\/caac.21657","journal-title":"CA Cancer J Clin"},{"key":"5019_CR23","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/jco.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK et al (2021) PRODIGY: A Phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 39:2903\u20132913. https:\/\/doi.org\/10.1200\/jco.20.02914","journal-title":"J Clin Oncol"},{"key":"5019_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234\u2013247. https:\/\/doi.org\/10.1016\/s1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"5019_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1067\/msy.2002.123769","volume":"131","author":"C Kunisaki","year":"2002","unstructured":"Kunisaki C, Shimada H, Nomura M et al (2002) Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Surgery 131:521\u2013528. https:\/\/doi.org\/10.1067\/msy.2002.123769","journal-title":"Surgery"},{"key":"5019_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/jco.2011.39.1953","volume":"30","author":"J Lee","year":"2012","unstructured":"Lee J, Lim DH, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268\u2013273. https:\/\/doi.org\/10.1200\/jco.2011.39.1953","journal-title":"J Clin Oncol"},{"key":"5019_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000360937","volume":"53","author":"L Lorenzon","year":"2014","unstructured":"Lorenzon L, Mercantini P, Ferri M et al (2014) Lymph-node ratio classification strongly correlates with cancer survivals of patients who underwent r0 resection for gastric cancer with more than 15 nodes harvested. Eur Surg Res 53:1\u201310. https:\/\/doi.org\/10.1159\/000360937","journal-title":"Eur Surg Res"},{"key":"5019_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","volume":"7","author":"SS Mehta","year":"2016","unstructured":"Mehta SS, Gelli M, Agarwal D, Go\u00e9r\u00e9 D (2016) Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol 7:225\u2013229. https:\/\/doi.org\/10.1007\/s13193-016-0504-6","journal-title":"Indian J Surg Oncol"},{"key":"5019_CR29","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"SS Mitsuru Sasako","year":"2011","unstructured":"Mitsuru Sasako SS, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with s-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387\u20134393","journal-title":"J Clin Oncol"},{"key":"5019_CR30","doi-asserted-by":"publisher","first-page":"912418","DOI":"10.1155\/2014\/912418","volume":"2014","author":"G Montori","year":"2014","unstructured":"Montori G, Coccolini F, Ceresoli M et al (2014) The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol 2014:912418. https:\/\/doi.org\/10.1155\/2014\/912418","journal-title":"Int J Surg Oncol"},{"key":"5019_CR31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","volume":"32","author":"SH Park","year":"2021","unstructured":"Park SH, Lim DH, Sohn TS et al (2021) A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 32:368\u2013374. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.017","journal-title":"Ann Oncol"},{"key":"5019_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396:635\u2013648. https:\/\/doi.org\/10.1016\/s0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"5019_CR33","volume-title":"International Union Against Cancer (UICC) TNM classification of malignant tumors","author":"LMKG Sobin","year":"2010","unstructured":"Sobin LMKG, Ch W (2010) International Union Against Cancer (UICC) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford","edition":"7"},{"key":"5019_CR34","doi-asserted-by":"publisher","first-page":"101042831771462","DOI":"10.1177\/1010428317714626","volume":"39","author":"Z Song","year":"2017","unstructured":"Song Z, Wu Y, Yang J, Yang D, Fang X (2017) Progress in the treatment of advanced gastric cancer. Tumour Biol 39:1010428317714626. https:\/\/doi.org\/10.1177\/1010428317714626","journal-title":"Tumour Biol"},{"key":"5019_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ssu.10042","volume":"21","author":"PH Sugarbaker","year":"2003","unstructured":"Sugarbaker PH, Yu W, Yonemura Y (2003) Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 21:233\u2013248. https:\/\/doi.org\/10.1002\/ssu.10042","journal-title":"Semin Surg Oncol"},{"key":"5019_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5019_CR37","doi-asserted-by":"publisher","first-page":"2135819","DOI":"10.1080\/2162402x.2022.2135819","volume":"11","author":"X Tang","year":"2022","unstructured":"Tang X, Li M, Wu X et al (2022) Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. Oncoimmunology 11:2135819. https:\/\/doi.org\/10.1080\/2162402x.2022.2135819","journal-title":"Oncoimmunology"},{"key":"5019_CR38","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B et al (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134:622\u2013628. https:\/\/doi.org\/10.1002\/ijc.28373","journal-title":"Int J Cancer"},{"key":"5019_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230\u2013240. https:\/\/doi.org\/10.1056\/NEJMoa1708618","journal-title":"N Engl J Med"},{"key":"5019_CR40","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426\u20132432. https:\/\/doi.org\/10.1245\/s10434-008-9966-2","journal-title":"Ann Surg Oncol"},{"key":"5019_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12957-019-1761-y","volume":"17","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen JQ, Liu JL, Tian L (2019) Issues on peritoneal metastasis of gastric cancer: an update. World J Surg Oncol 17:215. https:\/\/doi.org\/10.1186\/s12957-019-1761-y","journal-title":"World J Surg Oncol"},{"key":"5019_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4251\/wjgo.v12.i7.782","volume":"12","author":"TY Xie","year":"2020","unstructured":"Xie TY, Wu D, Li S et al (2020) Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer. World J Gastrointest Oncol 12:782\u2013790. https:\/\/doi.org\/10.4251\/wjgo.v12.i7.782","journal-title":"World J Gastrointest Oncol"},{"key":"5019_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/02656736.2014.893451","volume":"30","author":"RR Yarema","year":"2014","unstructured":"Yarema RR, Ohorchak MA, Zubarev GP et al (2014) Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-centre retrospective study. Int J Hyperth 30:159\u2013165. https:\/\/doi.org\/10.3109\/02656736.2014.893451","journal-title":"Int J Hyperth"},{"key":"5019_CR44","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1186\/s12885-020-07601-x","volume":"20","author":"P Yu","year":"2020","unstructured":"Yu P, Ye Z, Dai G et al (2020) Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study. BMC Cancer 20:1108. https:\/\/doi.org\/10.1186\/s12885-020-07601-x","journal-title":"BMC Cancer"},{"key":"5019_CR45","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1245\/s10434-021-11316-z","volume":"29","author":"JF Zhang","year":"2022","unstructured":"Zhang JF, Lv L, Zhao S, Zhou Q, Jiang CG (2022) Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with surgery: a 12-year meta-analysis of this promising treatment strategy for advanced gastric cancer at different stages. Ann Surg Oncol 29:3170\u20133186. https:\/\/doi.org\/10.1245\/s10434-021-11316-z","journal-title":"Ann Surg Oncol"},{"key":"5019_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.5754\/hge13038","volume":"60","author":"W Zhibing","year":"2013","unstructured":"Zhibing W, Qinghua D, Shenglin M et al (2013) Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Hepatogastroenterology 60:989\u2013994. https:\/\/doi.org\/10.5754\/hge13038","journal-title":"Hepatogastroenterology"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05019-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05019-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05019-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:12:10Z","timestamp":1693300330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05019-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":46,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5019"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05019-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Ethics Review Board of Zhejiang Cancer Hospital with Approval No. IRB-2016\u2013157 and was performed in line with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written informed consent was obtained from each study participant.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}